GH Secretagogues Β· MetabolicTier 1 β Strong clinical evidence (RCTs)
Tesamorelin
Egrifta Β· TH9507
FDA-approved GHRH analogue specifically indicated for HIV-associated lipodystrophy. Has the strongest clinical evidence for visceral fat reduction among GH peptides.
π SC injectionπ§ Refrigerate at 2β8Β°C; reconstituted: refrigerate, use within 28 days
Want a personalised protocol?
Our AI generator builds a protocol tailored to your profile and goals.
Mechanism of Action
Stabilised GHRH analogue that binds pituitary GHRH receptors, stimulating endogenous GH secretion. Particularly effective at mobilising visceral adipose tissue.
Clinical Applications
- βHIV-associated visceral lipodystrophy (FDA approved)
- βVisceral fat reduction in non-HIV patients (off-label)
- βMetabolic syndrome management
- βCognitive function improvement (emerging evidence)
- βCardiovascular risk factor reduction
Dosing Protocol
Recommended Dosing
SC injection. 1β2 mg once daily, typically in the morning. FDA-approved dose is 2 mg/day. Monitor IGF-1 and glucose quarterly.Safety & Contraindications
Possible Side Effects
- β Injection site reactions (most common)
- β Water retention
- β Joint and muscle pain
- β Peripheral oedema
- β Glucose elevation
Contraindications
- βActive malignancy
- βHypopituitarism
- βPregnancy
- βHistory of pituitary surgery or radiation
Combinations & Synergies
π Ipamorelincan enhance GH pulse with GHRH synergy
π AOD-9604complementary fat-reduction mechanisms